

Multidentate Small-Molecule Inhibitors of *Vaccinia* H1-Related (VHR) Phosphatase Decrease Proliferation of Cervix Cancer Cells[†]

Shuangding Wu,^{‡,§} Sofie Vossius,^{‡,§} Souad Rahmouni,^{‡,‡} Ana V. Miletic,[§] Torkel Vang,[§] Jesus Vazquez-Rodriguez,[§] Fabio Cerignoli,[§] Yutaka Arimura,[§] Scott Williams,[§] Tikva Hayes,[§] Michel Moutschen,[‡] Stefan Vasile,[§] Maurizio Pellecchia,[§] Tomas Mustelin,[§] and Lutz Tautz^{*,§}

[§]Infectious and Inflammatory Disease Center and Cancer Center, Burnham Institute for Medical Research, La Jolla, California 92037, and [‡]Immunology and Infectious Diseases Unit, GIGA-R, Liège University, Liège, Belgium. [‡]These authors contributed equally to this work.

Received July 10, 2009

Loss of VHR phosphatase causes cell cycle arrest in HeLa carcinoma cells, suggesting that VHR inhibition may be a useful approach to halt the growth of cancer cells. We recently reported that VHR is upregulated in several cervix cancer cell lines as well as in carcinomas of the uterine cervix. Here we report the development of multidentate small-molecule inhibitors of VHR that inhibit its enzymatic activity at nanomolar concentrations and exhibit antiproliferative effects on cervix cancer cells. Chemical library screening was used to identify hit compounds, which were further prioritized in profiling and kinetic experiments. SAR analysis was applied in the search for analogs with improved potency and selectivity, resulting in the discovery of novel inhibitors that are able to interact with both the phosphate-binding pocket and several distinct hydrophobic regions within VHR's active site. This multidentate binding mode was confirmed by X-ray crystallography. The inhibitors decreased the proliferation of cervix cancer cells, while growth of primary normal keratinocytes was not affected. These compounds may be a starting point to develop drugs for the treatment of cervical cancer.

Introduction

Protein tyrosine phosphatases (PTPs^d) have recently been implicated in various human diseases, including cancer, and have been suggested as potential drug targets.^{1–5} *Vaccinia* H1-related (VHR) phosphatase is a relatively small member of the subclass of dual-specificity phosphatases⁶ with only 185 amino acids (M_r 21 kDa) and no apparent targeting domain or docking site.⁷ Compared to the phospho-tyrosine (pTyr)-specific classical PTPs, the crystal structure of VHR revealed a much shallower active site, which allows VHR to act on both pTyr and phospho-threonine (pThr) in its substrates.⁸ VHR has been reported to dephosphorylate extracellular signal-regulated kinases Erk1/2 and c-Jun N-terminal kinases Jnk1/2, but not p38.^{9–11} These mitogen-activated protein kinases (MAP kinases) mediate major signaling pathways triggered by extracellular growth factor, stress, or cytokines,¹² and regulate cellular processes such as differentiation, proliferation, and apoptosis.^{13,14} MAP kinases are activated within the kinase cascade by phosphorylation at a Thr-X-Tyr motif in

their activation loop, whereas dephosphorylation of this motif by VHR or other MAP kinase phosphatases (MKPs) leads to a conformational change, leaving the kinase domain in an inactive, closed conformation.¹⁵

Unlike many MKPs, VHR expression is not induced in response to activation of MAP kinases⁹ but is instead regulated during cell cycle progression.¹⁶ Using RNA interference to knock down endogenous VHR, we have previously shown that HeLa cervix carcinoma cells that are lacking VHR arrested at the G1-S and G2-M transitions of the cell cycle and showed initial signs of senescence. Loss of VHR increased the expression of the cyclin-dependent kinase inhibitor p21^{Cip-waf1}, whereas genes of cell cycle regulators, DNA replication, transcription, and mRNA processing were downregulated.¹⁶ In addition, there have been several reports showing that prolonged activation of MAP kinase pathways results in cell cycle arrest and cell senescence.^{17–21}

In our recent study,²² we established a link between VHR and cervical cancer. We found VHR protein levels upregulated in several cervix cancer cell lines compared to normal keratinocytes, including human papillomavirus (HPV) positive cell lines CaSki, HeLa, and SiHa, as well as HPV negative cell lines HT3 and C33. Moreover, we also found higher expression levels of VHR in primary cervix cancer biopsies, including squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix.²² This suggested to us that VHR might be a novel and promising drug target for the treatment of cervical cancer and that small-molecule inhibitors of VHR should be valuable tools to validate this new target. Combining high-throughput chemical library screening and structure–activity relationship (SAR) analysis, we

[†]X-ray crystallography data was deposited at the PDB database and has the code 3F81.

*To whom correspondence should be addressed. Phone: 858-646-3100, ext 3640. Fax: 858-795-5225. E-mail: tautz@burnham.org.

^dAbbreviations: VHR, *Vaccinia* H1-related; PTP, protein tyrosine phosphatase; pTyr, phospho-tyrosine; pThr, phospho-threonine; Erk, extracellular signal-regulated kinase; Jnk, c-Jun N-terminal kinase; MAP, mitogen-activated protein; MKP, MAP kinase phosphatase; HPV, human papillomavirus; SAR, structure–activity relationship; pNPP, *p*-nitrophenyl phosphate; DiFMUP, 6,8-difluoro-4-methylumbelliferyl phosphate; DiFMU, 6,8-difluoro-7-hydroxy-4-methylcoumarin; DTT, dithiothreitol; rmsd, root-mean-square deviation.

developed compounds that specifically bind to VHR's active site in a multidentate fashion. This binding mode, which makes use of unique features at the protein surface surrounding the catalytic pocket, was confirmed by X-ray crystallography. Several of the inhibitors were active in cell-based assays at low micromolar concentrations and decreased the proliferation of cervix cancer cell lines significantly.

Results

Chemical Library Screening. A 96-well format in vitro assay was used to screen a set of 50000 drug-like molecules of the DIVERSet library from ChemBridge (ChemBridge, Inc.). At the used concentration of 0.02 mg/mL, 221 compounds inhibited VHR's enzymatic activity > 60% (average of $n = 2$) compared to a no-inhibitor control. For further evaluation, a total of 56 compounds were picked that inhibited VHR > 90% (average of $n = 2$). Michaelis–Menten kinetic studies revealed 21 hits that inhibited the enzyme with K_i values < 20 μM (Table 1). Clustering the 21 compounds by a Tanimoto distance²³ of 0.5 resulted in 12 different clusters and singletons, respectively, indicating a quite diverse chemical space covered by these molecules. The most active hit, 2-((*Z*)-4-oxo-5-((*E*)-3-phenylallylidene)-2-thioxothiazolidin-3-yl)ethane-sulfonic acid **1**, inhibited VHR with a K_i value of 0.81 μM . In a counter screen against the protein tyrosine phosphatases PTP1B, CD45, HePTP, Shp2, and YopH, only **1** and 1,4-dimethoxyanthracene-9,10-dione **8** were found to be selective for VHR (Figure 1). Of these two compounds, only **1** showed a clear competitive inhibition pattern as shown in the Lineweaver–Burk plot in Figure 2A.

In Silico Docking. To study the molecular basis for inhibition of VHR, we first used in silico docking to dock **1** and **8** into the active site of the VHR crystal structure (PDB code 1J4X, ref 24). Compound **8** failed to dock into the catalytic pocket, further supporting an inhibition mechanism other than competitive. Because quinones like **8** are known to deactivate PTPs by oxidizing the catalytic cysteine residue,²⁵ we discarded **8** from further investigation. As for compound **1**, the docking suggested that the sulfonic acid moiety functions as a phosphate mimic and binds into the catalytic pocket, forming a network of hydrogen bond interactions with the phosphate binding loop, also called P-loop (Figure 2B). In support of this, similar compounds lacking the sulfonic acid moiety did not inhibit VHR. Furthermore, the docking suggested that the oxo-thioxothiazolidine ring interacts with the rim of the catalytic pocket, whereas the diene linker and the phenyl ring make van der Waals interactions with a hydrophobic region, mainly formed by Leu25 and Tyr128 (Figure 2B).

SAR Analysis and Analogs of Lead Compound 1. By further analyzing the lipophilic potential of VHR's active site surface area, we found a total of three distinct hydrophobic regions surrounding the catalytic pocket (Figure 2B). Compared to active site properties of solved PTP structures and homology models,²⁶ this feature seems to be rather unique to VHR and, therefore, could be exploited for designing selective inhibitors. The exposed hydrophobic patches are formed by Leu25/Tyr128 and Leu16/Tyr23, which make up large portions of the substrate binding site,²⁴ as well as by Phe68/Met69, which is part of a loop opposite of the catalytic pocket (Figure 2B). In an attempt to find analogs of **1** that could target more than one of these hydrophobic regions, we kept the oxo-thioxothiazolidinyl-ethanesulfonic acid moiety

Table 1. Most Potent VHR Screening Hits^a

#	Structure*	Mol. Weight	K_i , μM
1		355.441	0.809
2		451.4374	1.76
3		332.3482	1.86
4		395.4902	2.01
5		261.338	2.09
6		364.1547	2.64
7		368.4522	2.94
8		268.2684	3.07
9		429.9075	3.13
10		377.2549	3.19
11		331.7759	3.49
12		442.8605	3.87
13		454.2384	4.44
14		395.2022	12.1
15		231.2506	12.8
16		385.0484	13.4
17		267.2404	13.8
18		352.3056	13.8
19		288.3204	15.8
20		359.208	15.9
21		481.2585	16.2

^a K_i value < 20 μM . * Compounds **11**, **13**, **19**, and **21** are mixtures of *E/Z*-isomers.

as hydrophilic pharmacophore, and subjected it to a substructure search among commercially available compounds. Nine structures were identified that fulfilled the requirement of having additional multiple hydrophobic entities to interact with multiple hydrophobic regions in VHR's active site. All compounds contained a 1-phenyl-substituted pyrazole ring, which at its 3-position linked to another, more variable entity (Table 2). We obtained all nine analogs and subjected them to direct measurements of VHR inhibition. Indeed, compounds **SA1**, **SA2**, **SA3**, **SA4**, and **SA5** showed excellent




Figure 1. Profiling of the 21 most active VHR screening hits at 20 μM against VHR, PTP1B, CD45, HePTP, Shp2, and YopH. Black arrows indicate compounds **1** and **8**, which were found to be selectively inhibiting VHR.




Figure 2. Characterization of compound **1** (A) Michaelis–Menten kinetic measurements, Lineweaver–Burk plot for **1** with VHR. (B) FlexX docking of **1** into the active site of VHR crystal structure (PDB code 1J4X). The color code of the MOLCAD surface represents the lipophilic potential (brown: most hydrophobic, blue: most hydrophilic).

IC_{50} values of 18, 71, 74, 78, and 268 nM, respectively (Table 2). An aromatic group in position 'R', such as the benzyloxy group in compounds **SA1–4**, seemed to be very well accommodated by the protein, whereas sterically more demanding structures, such as the piperidinsulfonyl group in **SA5** or the morpholinosulfonyl group in **SA8**, were less favorable. On the other hand, groups such as methoxy in **SA6** or methyl in **SA9** seemed to be too small to provide additional binding energy through van der Waals interactions. Interestingly, compounds **SA1–4** only differ in their substituents at the benzyloxy group. Chlorine in the *para*-position was most favorable (**SA1**), whereas substituents in the *ortho*-position, such as chlorine (**SA2**) or fluorine (**SA3**),

had no effect on inhibitory activity against VHR *in vitro*. Testing the five best inhibitors (**SA1–5**) against a panel of related PTPs demonstrated that they were at least 1 order of magnitude less potent for MKP-1, CD45, Cdc25A, PTP1B, and HePTP (Table 2). Of these phosphatases, MKP-1 and HePTP share the same physiological substrate with VHR, namely, the MAP kinase Erk, and MKP-1 is structurally closely related to VHR.

Cocrystallization and X-ray Structure Analysis. To investigate the nature of the multidentate binding of our inhibitors experimentally, we attempted to solve the crystal structure of **SA3** bound to VHR. Using the hanging-drop vapor diffusion technique and repeated macroseeding, we obtained cocrystals of the VHR-**SA3** complex. The structure was solved to 1.9 Å resolution by molecular replacement. Refinement statistics for the complex are presented in Table 3; R factor and R_{free} values were 17.8 and 21.9%, respectively. After refinement, difference maps ($F_o - F_c$ and $2F_o - F_c$) were used to fit the inhibitor. Clear electron density of **SA3** in the VHR active site was visible for the oxo-thioxothiazolidinyl-ethanesulfonic acid moiety (Figure 3B). This moiety occupies the phosphate-binding pocket in VHR, representing the exact same position and orientation as the phosphotyrosine group of a substrate peptide found in the 1J4X.pdb structure (ref 24, Figure 3A). Thereby, the sulfonic acid group undergoes multiple hydrogen bond interactions with backbone nitrogen atoms of the P-loop, and forms a salt bridge with the guanidinium group of Arg130 (Figure 3B). Modeling of **SA3** into the visible electron density clearly exhibited the multidentate binding mode of the inhibitor, including van der Waals interactions of the fluoro-benzyloxy group with Leu16/Tyr23, and the phenyl-pyrazole ring with Phe68/Met69 in VHR (Figure 3C). Modeling also indicated that the **SA3** hydrophobic entities might have some flexibility in interacting with these amino acid residues, which could be the reason for the not defined electron density for these parts of the molecule. In any case, however, modeling of **SA3** into the visible electron density always found the fluoro-benzyloxy and phenyl-pyrazole groups interacting with multiple hydrophobic patches in a bidentate fashion. Comparison of the VHR-**SA3** complex with the previously reported VHR structure (1J4X.pdb) also supported our binding model. Significant differences in the side chain positions of Tyr23, Phe68, and Met69 were observed, which account for specific interactions with **SA3** (Figure 3A). Moreover, parts of the substrate recognition loop immediately following the N-terminal helix $\alpha 1$ (residues Ser17, Asp18, Gly19, Ser20, Gly21, and Cys22) were shifted by as much as 5.7 Å, compared to 1J4X.pdb, most likely to accommodate the fluoro-benzyloxy group of **SA3** and to avoid unfavorable interactions between **SA3** and hydrophilic amino acid residues within this loop region.

Proliferation of Cervix Cancer Cells. We recently found VHR protein levels upregulated in several cervix cancer cell lines, as well as in primary cervix cancer biopsies.²² We also reported that VHR was necessary for proliferation of HeLa cervix carcinoma cells.¹⁶ Therefore, we set out to determine the effects of our five best VHR inhibitors on cervix cancer cell lines HeLa and CaSki, as well as on primary normal keratinocytes. As shown in Figure 4A, proliferation of primary normal keratinocytes, as measured by cell numbers, was not affected by any of the inhibitors after 24 h incubation at a concentration of 20 μM . In contrast, compounds **SA1–5** significantly inhibited the spontaneous proliferation of

Table 2. In Vitro Efficacy and Selectivity of 1-Phenylpyrazole Derivatives

	R	IC ₅₀ , μ M						
		VHR	MKP-1	Cdc25A	HePTP	CD45	PTP1B	
	SA1		0.018	0.46	2.4	0.62	0.46	0.46
	SA2		0.071	0.47	3.4	1.2	0.30	0.59
	SA3		0.074	0.52	2.8	0.87	0.50	0.42
	SA4		0.078	0.78	3.4	1.5	0.61	1.8
	SA5		0.27	2.8	>10	2.4	1.8	2.2
	SA6	CH ₃ -O	1.8	nd	nd	nd	nd	nd
	SA7	Cl	1.8	nd	nd	nd	nd	nd
	SA8		2.4	nd	nd	nd	nd	nd
	SA9	CH ₃	3.1	nd	nd	nd	nd	nd

Table 3. Summary of Crystallographic Data and Refinement Statistics for the VHR-SA3 Complex^a

Crystallographic Data	
space group	P2 ₁
unit cell (\AA)	$a = 50.406, b = 59.186, c = 60.656$ $a = 90.00, b = 98.36, g = 90.00$
molecules/asymmetric unit	two monomers
resolution range (\AA)	50–1.9
data completeness (%)	99.1 (99.7)
unique reflections	26330 (2028)
redundancy	6.8
R_{sym} (%)	5.9
Refinement Statistics	
R factor (%)	17.8 (18.4)
R_{free} (%)	21.9 (23.6)
avg B factor (\AA^2)	15.5
No. protein atoms	2784
No. inhibitor atoms	28
No. water atoms	227
rmsd bond length (\AA)	0.016
rmsd bond angle	1.724

^a Values for the highest resolution shell (1.95–1.90 \AA) are given in parentheses.

HeLa cells, compared to a DMSO control, with SA3 being the most effective one, reducing HeLa cell numbers to less than 50% (Figure 4A). In a second assay, we measured proliferation of HeLa and Caski cells by following the incorporation of tritium (³H) labeled thymidine into the DNA (Figure 4B,C). A clear antiproliferative effect was found for all compounds, though more pronounced in CaSki compared to HeLa cells. In HeLa cells, SA3 revealed the best antiproliferative effect, reducing cell growth by as much as

58% compared to DMSO alone. For all other compounds, the inhibition did not exceed 30% (Figure 4B). In CaSki cells, however, all inhibitors reduced the spontaneous proliferation by more than 50%, with SA3 being most effective, decreasing the proliferation by as much as 74% (Figure 4C). To exclude that this decrease in cell proliferation was due to apoptosis, we incubated HeLa and Caski cells with 20 μ M SA3 or SA2 for 24 h, stained cells with AnnexinV and propidium iodide (PI), and used flow cytometry to determine the percentage of apoptotic cells. As Figure 4D clearly shows, there was no difference between the percentages of AnnexinV/PI negative cells in samples treated with the inhibitors or treated with the vehicle, clearly indicating that the observed antiproliferative effect of the compounds was not due to apoptosis.

Discussion and Conclusions

In this study we used high-throughput chemical library screening in a first step to generate hits for VHR, which were further prioritized through Michaelis–Menten kinetic studies and counter screens against a number of structurally related phosphatases. The resulting lead compound **1** competitively inhibited VHR with a K_i value of 0.81 μ M and exhibited a promising degree of selectivity for VHR among other PTPs. In silico docking of **1** into the active site of VHR and SAR analysis suggested a binding mode, in which the sulfonic acid moiety of **1** binds through a network of hydrogen bond interactions into the phosphate binding pocket, whereas the thiazolidine heterocycle interacts with the rim of the pocket and the phenyl-allyl moiety makes van der Waals interactions with side chains of hydrophobic amino acids that flank the active site.




Figure 3. X-ray structural analysis of the VHR-SA3 complex. (A) Stereo ribbon diagram of the overall cocrystal structure of the VHR-SA3 complex (green), aligned with X-ray coordinates of a VHR-substrate peptide complex (1J4X.pdb, VHR gray, peptide light-blue). Tyr23, Phe68, and Met69 (green and gray, respectively), as well as the oxo-thioxothiazolidinyl-ethanesulfonic acid moiety of SA3 (magenta) and pTyr from the peptide (light-blue) are highlighted in stick representation. (B) Close-up of SA3 bound to VHR's active site with visible electron density. Yellow dashed lines indicate hydrogen bond interactions of the sulfonic acid moiety with amino acid residues of the P-loop at the bottom of the catalytic pocket. (C) Modeling of SA3 into visible electron density. White arrows indicate multiple van der Waals interactions with hydrophobic regions at the surface surrounding VHR's catalytic pocket.

The sulfonic acid headgroup is an ideal chemical structure to mimic a phosphate group without undergoing any hydrolysis reaction. Phosphorus and sulfur atoms have similar atomic and van der Waals radii, and are coordinated by four (phosphate) or three (sulfonate) oxygen atoms, respectively. However, under physiological pH conditions, a phosphate group carries two negative charges, whereas the sulfonate has only one, making it easier for compounds carrying the latter to penetrate cell membranes. We therefore decided to keep the oxo-thioxothiazolidinyl-ethanesulfonic acid moiety of **1** as pharmacophore and applied a structure-based approach to optimize **1** in terms of both potency and selectivity.

Examination of the surface area that surrounds the active site in VHR revealed several distinct hydrophobic regions that were exploited in the design of more potent and selective inhibitors. A search for compounds that would still bind to the catalytic pocket, and additionally could interact with not just one but multiple hydrophobic areas in a multidentate fashion resulted in five molecules with significant lower IC_{50} values than lead structure **1**. These compounds contain a thioxothiazolidinyl-ethanesulfonic acid moiety, representing the defined pharmacophore in **1**. In addition, a pyrazole ring functions as a linker from which two hydrophobic entities branch off: a phenyl ring in 1-position and a more variable group at 3-position. Cocrystallization of VHR with one of these compounds, SA3, yielded a crystal structure in which clear electron density of SA3 was observed for the thioxothiazolidinyl-ethanesulfonic acid moiety. As predicted by the docking studies, the sulfonic acid group was found to bind tightly into the catalytic pocket, mimicking the phosphate group of the natural substrate. No clear electron density was observed for the two hydrophobic entities of SA3, which is most likely due to some degree of flexibility in the interactions between these

parts of the molecule and the hydrophobic amino acid residues of the protein. Nonetheless, modeling of SA3 into the visible electron density leaves no doubt about the bidentate fashion that SA3 employs to bind to distinct hydrophobic patches at the surface that flanks the catalytic pocket in VHR. Besides highly improved potency against VHR with IC_{50} values as low as 18 nM, these multidentate inhibitors were at least 1 order of magnitude less potent for any other PTP tested, including HePTP and MKP-1, which share the same physiological substrate with VHR. This result provides a good example for a general applicable concept, in which targeting unique surface features outside of the catalytic pocket can generate selective small-molecule inhibitors for individual members of the PTP family.

We also present several lines of evidence strongly suggesting that our VHR inhibitors are able to pass cell membrane barriers and target VHR in cultured cells. In particular, we tested our compounds in cervical cancer cells, which were shown earlier to express higher levels of endogenous VHR compared to noncancerous cells of the cervix. Indeed, incubation of the cancer cell lines HeLa and CaSki with the inhibitors at 20 μ M induced a very significant inhibition of cell proliferation after an incubation period as short as 24 h. This inhibition of cell growth was not due to cell death and is also in accordance with our previous work, demonstrating that loss of VHR using RNAi induces a dramatic decrease of HeLa cell numbers and proliferation. It is interesting to note that SA3 was more effective in inhibiting proliferation than SA1, although its IC_{50} value is four times higher in vitro. SA3 also exhibited greater antiproliferative effects than SA2 and SA4, both of which share similar IC_{50} values with SA3 in vitro. These results suggest a beneficial role for the fluorine substituent (which is only present in SA3), maybe by facilitating




Figure 4. Effects of VHR inhibitors on proliferation and survival of cervix cancer cells. (A) Cell numbers of HeLa cervix carcinoma cells and normal keratinocytes (NK) after 24 h of treatment with 20 μ M inhibitors, given as percentage of the DMSO control. (B,C) [³H]-Thymidine incorporation assay with 20 μ M inhibitors or vehicle (DMSO) in HeLa (B) or Caski (C) cervix cancer carcinoma cells. (D) Survival/death of HeLa and CasKi cells in presence of 20 μ M inhibitors or DMSO after 24 h, evaluated by AnnexinV-FITC/PI flow cytometry assay (FACS Vantage, BD). Percentage of live cells (Annexin V negative and PI negative cells on flow cytometry dot plots) is given. All data are reported as mean \pm SD from three independent experiments.

better membrane permeability. The latter could be a limiting factor for these compounds, considering the substantially higher concentration that is needed to see clear effects in cells vs inhibition of recombinant protein. Nonetheless, the fact that our inhibitors are not toxic to cells with low levels of endogenous VHR, such as primary normal keratinocytes, these compounds may well be a starting point to develop

drugs for the treatment of cervical cancer and perhaps other cancers. Indeed, our results provide first evidence that pharmacological inhibition of VHR could be beneficial in treating such diseases. However, additional studies will be necessary to get better insights into the role of VHR phosphatase in cell cycle regulation and cancer and to test the activity of these compounds in vivo using mouse models.

Materials and Methods

Reagents. *p*-Nitrophenyl phosphate (*p*NPP) was purchased from Sigma-Aldrich (St. Louis, MO). BIOMOL GREEN reagent was from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA). 6,8-Difluoro-4-methylumbelliferyl phosphate (DiFMUP) was from Invitrogen Inc. (Carlsbad, CA). The 56 hit compounds were purchased from ChemBridge Inc., the sulfonic acid compounds were from Sigma, and all compounds had a purity of >95%. All other chemicals and reagents were of the highest grade available commercially. The anti-VHR monoclonal antibody was from Transduction Laboratories (Los Angeles, CA). Anti-Erk and anti-p38 were from Cell Signaling Technology Inc. (Beverly, MA); anti-phospho-Erk and anti-phospho-p38 were from Promega (Madison, WI).

Recombinant PTPs. Recombinant VHR, HePTP, and YopH were expressed in *E. coli* and purified as described previously.²⁰ Recombinant CD45, PTP1B, MKP-1, and Cdc25A were purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA). Shp2 was generously provided by Dr. Gen-Sheng Feng.

Chemical Library Screening. A set of 50000 drug-like molecules from the DIVERSet library (ChemBridge, Inc.) was screened in a 96-well format in vitro phosphatase assay. Compounds had a working concentration of 0.15 mg/mL in 10% DMSO. Each reaction contained 180 nM VHR, 4 mM *p*NPP, and 0.02 mg/mL compound in 0.1 M Bis-Tris pH 6.0 reaction buffer with 1 mM dithiothreitol (DTT) present. The final volume amounted to 70 μ L and contained 1.4% DMSO. The reaction was initiated by addition of *p*NPP after a preincubation of the enzyme with compounds for 10 min at room temperature. After 15 min, the reaction was quenched by addition of 140 μ L BIOMOL GREEN reagent, and the *p*NPP hydrolysis was determined by measuring the absorbance of the complexed free phosphate at 620 nm. The nonenzymatic hydrolysis of the substrate was corrected by measuring the negative control without addition of enzyme. Other controls included a positive control (no inhibitor added), a background control (no substrate added), and a control with 200 μ M of the general PTP inhibitor sodium orthovanadate. To quantitate the inhibitory efficacy of the library compounds, we determined the ratio of inhibition in comparison to the positive control. Every compound with >60% inhibition was cherry-picked and rescreened to confirm it as a hit.

IC₅₀ Measurements. The PTP-catalyzed hydrolysis of 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) in the presence of compound was assayed at 30 $^{\circ}$ C in a 60 μ L 96-well format reaction system in 150 mM Bis-Tris, pH 6.0, assay buffer having an ionic strength of 150 mM (adjusted with NaCl) and containing 1 mM DTT and 5% DMSO. At various concentrations of the compound, the initial rate at fixed DiFMUP concentration (equal to the corresponding K_m value for each PTP) was determined using a FLx800 microplate reader (Bio-Tek Instruments, Inc.), an excitation wavelength of 360 nm, and measuring the emission of the fluorescent reaction product 6,8-difluoro-7-hydroxy-4-methylcoumarin (DiFMU) at 460 nm. The nonenzymatic hydrolysis of the substrate was corrected by measuring the control without addition of enzyme. The IC₅₀ value was determined by plotting the relative activity versus inhibitor concentration and fitting to eq 1 using the software GraphPad Prism (GraphPad

Software, Inc.).

$$V_i/V_0 = IC_{50}/(IC_{50}+[I]) \quad (1)$$

In this case, V_i is the reaction velocity when the inhibitor concentration is $[I]$, V_0 is the reaction velocity with no inhibitor, and $IC_{50} = K_i + K_i[S]/K_m$.

K_i Determination. The same format and buffer system as for IC_{50} measurements was used, where the enzyme was preincubated with various fixed concentrations of inhibitors for 10 min. The reaction was initiated by addition of various concentrations of p NPP (ranging from 0.2 to 10 K_m) to the reaction mixture. The initial rate was determined using an ELx808 microplate reader (Bio-Tek Instruments, Inc.), reading the absorbance of the product p -nitrophenol at 404 nm. The nonenzymatic hydrolysis of the substrate was corrected by measuring the control without addition of enzyme. The inhibition constant and inhibition pattern was evaluated by fitting the data to the Michaelis–Menten equations for either competitive, uncompetitive, or mixed inhibition as described before,²⁷ using nonlinear regression and the program GraphPad Prism (GraphPad Software, Inc.). For a comparison of the fitting results, the second-order Akaike's Information Criterion (AICc) was calculated as previously described.²⁷

Molecular Modeling and In Silico Docking. Molecular modeling studies were conducted on a Linux workstation with the software package SYBYL version 7.1 (TRIPOS). Energy-minimized molecular models of the compounds were generated by the SYBYL/CONCORD routine. Flexible ligand docking calculations were performed with FlexX as implemented in Sybyl. For each compound, 30 solutions were generated and ranked by their FlexX score and CSCORE. The coordinates of the three-dimensional structure of the catalytic domain of VHR (PDB code 1J4X, ref 24) were used in the docking studies, and the binding pocket was defined as an 8 Å radius within the catalytic cysteine 124. Molecular surfaces were generated with MOLCAD as implemented in Sybyl. The chemical clustering uses Tanimoto distance as calculated with the program ICM Pro (Molsoft, Inc.), which, by default, uses binary fingerprints of the molecular properties.

Cocrystallization of VHR with Compound SA3. VHR (amino acids 3–185) was subcloned into pGEX vector (GE Healthcare Life Sciences), overexpressed in *E. coli* BL21 (DE3), and purified as GST-fusion protein by affinity chromatography (glutathione sepharose 4B). After cleavage of GST by thrombin digestion and purification by gel filtration, the purified enzyme was stored at -20 °C in 50 mM Tris pH 7.4, 1 mM EDTA, and 10 mM DTT. The recombinant protein was confirmed by mass spectroscopy, finding a molecular weight of 20259.3 Da compared to the predicted molecular weight of 20260.0 Da. For crystallization, the stocked VHR was mixed with inhibitor SA3 to a final concentration of 0.37 mM VHR and 1.0 mM SA3, respectively. When the hanging-drop vapor diffusion technique was used, VHR-SA3 was crystallized in the hanging drop of 2 mL of protein solution mixed with 2 mL of reservoir solution (100 mM Tris pH 7.4, 15% polyethylene glycol 8000, 60 mM NaF) at 24 °C. The crystals for data collection were obtained by repeated macroseeding. The crystal was flash frozen in a stream of nitrogen gas to 140 K. The diffraction data was collected using a R-AXIS IV detector with a wavelength of 1.5418 Å and oscillation of 1°. The data were processed using the HKL2000 program package.²⁸ The structure of the VHR-SA3 complex was solved with molecular replacement using a reported VHR crystal structure (PDB code 1VHR, ref 8) as search model and the program Molrep as implemented in CCP4.²⁹ An iterative process of refinement in CCP4 and model building using the program Coot³⁰ was used to construct the model of the complex. The SA3 ligand dictionary file used in CCP4 and Coot was generated with PRODRG.³¹ After refinement, difference maps ($F_o - F_c$ and $2F_o - F_c$) were used to fit the inhibitor. Clear electron density was visible for only the partial inhibitor in the

VHR active site. Refinement statistics for the complex are presented in Table 2. For the final structure, R factor and R_{free} values were 17.8 and 21.9%, respectively. Graphic images presented in the figures were prepared with PyMol (DeLano Scientific, Palo Alto, CA).

Cell Lines and Primary Keratinocytes. HeLa and CaSki cells were grown in DMEM medium (Dulbecco's modified Eagle's medium; ICN; low Laboratories) complemented with 10% (v/v) heat inactivated fetal calf serum (FCS), 30 units/mL of penicillin, 30 μ g/mL of streptomycin, 1 mM sodium pyruvate, 1% (v/v) nonessential amino acids (100 \times), and 2 mM of L-glutamine. Normal keratinocytes were prepared from hysterectomies as described previously.²² Briefly, fragments were plunged in a solution containing gentamycin, fungizon, and antimycoplasm. These fragments were cut in smaller pieces and then incubated in trypsin-EDTA (Invitrogen) at 37 °C under agitation for 1–2 h. The epithelium was scraped and cells were recovered in FCS. After centrifugation, the cells were resuspended in K-SFM medium (serum-free media; Invitrogen) complemented with EGF (0.1 ng/mL), pituitary hormone (20–30 μ g/mL), and gentamycin (5 μ g/mL).

Cell Proliferation, Survival, and Apoptosis Assays. To evaluate the effect of the inhibitors on viability and apoptosis of HeLa and CaSki cells and primary normal keratinocytes, 10^5 cells were incubated for 24 h with 20 μ M of the different inhibitors or with the vehicle (DMSO). Cells were then trypsinized and counted on a thomacytometer plate using trypan blue. Both death (blues cells) and live cells were counted. Half of the collected cells were stained with Annexin V and propidium iodide and analyzed by flow cytometry to evaluate the percentage of apoptotic and death cells. Proliferation assays were performed by incubation of 5×10^4 HeLa or CaSki cells in 200 mL of DMEM complete medium in flat-bottomed 96-well microtiter plates. Proliferation was analyzed after incubating cells for 24 h with 20 μ M inhibitors or DMSO, adding [³H]thymidine (0.4 mCi) for the last 4 h, before collecting cells with a cell harvester (Skatron, Sterling, VA) onto glass fiber filters, and counting radioactivity using a scintillation analyzer (Tri-Carb, Packard, Meriden, CT).

Acknowledgment. This work was supported by Grant IR21CA132121 (to L.T.) from the National Institutes of Health and by a grant from the Fond de la Recherche Scientifique (FRS-FNRS) and Télévie (to S.R.).

References

- Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-generation drugs? *Angew. Chem., Int. Ed.* **2005**, *44*, 3814–3839.
- Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. *Nat. Rev. Mol. Cell Biol.* **2006**, *7*, 833–846.
- Ostman, A.; Hellberg, C.; Bohmer, F. D. Protein-tyrosine phosphatases and cancer. *Nat. Rev. Cancer* **2006**, *6*, 307–320.
- Tautz, L.; Pellecchia, M.; Mustelin, T. Targeting the PTPome in human disease. *Expert Opin. Ther. Targets* **2006**, *10*, 157–177.
- Jiang, Z. X.; Zhang, Z. Y. Targeting PTPs with small molecule inhibitors in cancer treatment. *Cancer Metastasis Rev.* **2008**, *27*, 263–272.
- Alonso, A.; Sasin, J.; Bottini, N.; Friedberg, I.; Friedberg, I.; Osterman, A.; Godzik, A.; Hunter, T.; Dixon, J.; Mustelin, T. Protein tyrosine phosphatases in the human genome. *Cell* **2004**, *117*, 699–711.
- Ishibashi, T.; Bottaro, D. P.; Chan, A.; Miki, T.; Aaronson, S. A. Expression cloning of a human dual-specificity phosphatase. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89*, 12170–12174.
- Yuvaniyama, J.; Denu, J. M.; Dixon, J. E.; Saper, M. A. Crystal structure of the dual specificity protein phosphatase VHR. *Science* **1996**, *272*, 1328–1331.
- Alonso, A.; Saxena, M.; Williams, S.; Mustelin, T. Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation. *J. Biol. Chem.* **2001**, *276*, 4766–4771.

- (10) Todd, J. L.; Rigas, J. D.; Rafty, L. A.; Denu, J. M. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). *Oncogene* **2002**, *21*, 2573–2583.
- (11) Todd, J. L.; Tanner, K. G.; Denu, J. M. Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. *J. Biol. Chem.* **1999**, *274*, 13271–13280.
- (12) Waskiewicz, A. J.; Cooper, J. A. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. *Curr. Opin. Cell Biol.* **1995**, *7*, 798–805.
- (13) Robinson, M. J.; Cobb, M. H. Mitogen-activated protein kinase pathways. *Curr. Opin. Cell Biol.* **1997**, *9*, 180–186.
- (14) Ip, Y. T.; Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK)—from inflammation to development. *Curr. Opin. Cell Biol.* **1998**, *10*, 205–219.
- (15) Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. *Cell* **1997**, *90*, 859–869.
- (16) Rahmouni, S.; Cerignoli, F.; Alonso, A.; Tsutji, T.; Henkens, R.; Zhu, C.; Louis-dit-Sully, C.; Moutschen, M.; Jiang, W.; Mustelin, T. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. *Nat. Cell Biol.* **2006**, *8*, 524–531.
- (17) Woods, D.; Parry, D.; Cherwinski, H.; Bosch, E.; Lees, E.; McMahon, M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21 Cip1. *Mol. Cell. Biol.* **1997**, *17*, 5598–5611.
- (18) Sewing, A.; Wiseman, B.; Lloyd, A. C.; Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21 Cip1. *Mol. Cell. Biol.* **1997**, *17*, 5588–5597.
- (19) Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **1997**, *88*, 593–602.
- (20) Pumiglia, K. M.; Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 448–452.
- (21) Wang, W.; Chen, J. X.; Liao, R.; Deng, Q.; Zhou, J. J.; Huang, S.; Sun, P. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. *Mol. Cell. Biol.* **2002**, *22*, 3389–3403.
- (22) Henkens, R.; Delvenne, P.; Arafa, M.; Moutschen, M.; Zeddou, M.; Tautz, L.; Boniver, J.; Mustelin, T.; Rahmouni, S. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. *BMC Cancer* **2008**, *8*, 147.
- (23) Willett, P. Similarity-based virtual screening using 2D fingerprints. *Drug Discovery Today* **2006**, *11*, 1046–1053.
- (24) Schumacher, M. A.; Todd, J. L.; Rice, A. E.; Tanner, K. G.; Denu, J. M. Structural basis for the recognition of a bisphosphorylated MAP kinase peptide by human VHR protein Phosphatase. *Biochemistry* **2002**, *41*, 3009–3017.
- (25) Tautz, L.; Mustelin, T. Strategies for developing protein tyrosine phosphatase inhibitors. *Methods* **2007**, *42*, 250–260.
- (26) Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Müller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome. *Cell* **2009**, *136*, 352–363.
- (27) Tautz, L.; Bruckner, S.; Sareth, S.; Alonso, A.; Bogetz, J.; Bottini, N.; Pellecchia, M.; Mustelin, T. Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. *J. Biol. Chem.* **2005**, *280*, 9400–9408.
- (28) Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. *Methods Enzymol.* **1997**, *276*, 307–326.
- (29) Collaborative Computational Project, No. 4. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **1994**, *50*, 760–763.
- (30) Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2004**, *60*, 2126–2132.
- (31) Schüttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2004**, *60*, 1355–1363.